St. Jude Medical Announces Completion of European Enrollment in its Trifecta Stented Tissue Valve Trial

ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ) today announced that it has completed enrollment in its European clinical trial to evaluate Trifecta™, a stented pericardial tissue heart valve.